stockrowBioNTech SE Sponsored ADR
BNTX Healthcare Biotechnology
BioNTech SE Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 9.07% from fiscal 2024.
- Revenue
- −16.4%
- EPS
- +708.4%
- Free cash flow
- −123.8%
- Total debt
- +44.4%
Quarter to September 2026, against a year earlier
Follow BNTX
Alert me
BioNTech SE Sponsored ADR (BNTX) Price to free cash flow
BioNTech SE Sponsored ADR has no meaningful price to free cash flow: its trailing twelve-month free cash flow is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 71.9× (December 2021) — the current reading is the lowest in ten years.
Price to free cash flow, daily
Embed this chart
Annual newest first
| Period | Price to free cash flow | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 5.4× | 106.07% |
| FY2022 | 2.6× | (96.39%) |
| FY2021 | 71.9× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | Price to free cash flow | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 47.1× | 17.85% |
| Mar 2026 | 39.9× | — |
| Dec 2025 | 0.0× | — |
| 24 more quarters | Free account |
Against its own ten years
Price to free cash flow against peers
| Company | Price to free cash flow |
|---|---|
| ROIV Roivant Sciences Ltd. compare | n/m |
| GMAB Genmab A/S Sponsored ADR compare | n/m |
| BNTX BioNTech SE Sponsored ADR | n/m |
| BBIO BridgeBio Pharma, Inc. compare | n/m |
| INSM Insmed, Inc. compare | n/m |
| EXEL Exelixis, Inc. compare | 14.8× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 26.1× |
| INCY Incyte Corporation compare | 35.3× |
| ASND Ascendis Pharma A/S compare | 42.1× |
| Biotechnology industry median | 24.8× |
| Healthcare sector median | 21.1× |
| Market median | 14.1× |
What Price to free cash flow is
Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.
Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))
More on BNTX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Beneish M-score
- The full statement